Core Viewpoint - The A-share market showed strong performance in August, with major indices rising significantly, yet the excess returns of stock strategy private equity products were disappointing, marking the worst monthly performance of the year [1][2]. Group 1: Market Performance - In August, the Shanghai Composite Index rose by 7.97%, the Shenzhen Component Index increased by 15.32%, and the ChiNext Index surged over 24% [1]. - Despite the strong market, the average excess return of 3,122 stock strategy private equity products was -1.97%, the worst monthly performance this year [1]. Group 2: Quantitative vs. Subjective Strategies - Quantitative private equity products experienced a notable decline, with an average excess return of -3.94% in August, while subjective private equity products had an average excess return of -1.00% [1]. - The significant decline in quantitative products is attributed to a reversal in style, particularly the outperformance of large-cap stocks over small-cap stocks, and severe sector differentiation due to rapid growth in financing scale [1][2]. Group 3: Consistent Performers - As of August 2025, only 95 stock strategy private equity products achieved positive excess returns for eight consecutive months, representing about 3% of the total [2]. - Among private equity firms with over 10 billion in assets, 46 products achieved positive excess returns for eight consecutive months, all of which were quantitative products, with an average excess return of 0.63% in August and 17.91% year-to-date [3]. Group 4: Top Performers by Asset Size - In the 20-100 billion category, 14 products achieved positive excess returns for eight consecutive months, with an average excess return of 1.83% in August and 22.48% year-to-date [7]. - The top three products in this category were "New Thinking Multi-Strategy 3", "Pansong Micro-Cap Index Enhanced 1", and "Giraffe 7", with year-to-date excess returns of ***% [11]. Group 5: Small and Emerging Firms - In the 5-20 billion category, 13 products achieved positive excess returns for eight consecutive months, with an average excess return of 5.34% in August and 57.58% year-to-date [13]. - The leading product in the 0-5 billion category was "Zijin Yunsong", achieving a year-to-date excess return of ***% [18].

Core Viewpoint - In August, A-shares experienced a significant rally, with the Shanghai Composite Index reaching a nearly 10-year high and the ChiNext Index rising over 24% in a single month. The total market turnover and financing balance remained at historical highs, indicating active trading in the market [1][2]. Group 1: Market Performance - The total number of private equity products under billion-yuan private equity firms that reached historical net value highs in August is 456, accounting for 91.57% of the total products with performance displayed on the private equity platform [1]. - Among these products, quantitative products accounted for 297, while non-quantitative products accounted for 159. The majority of products employed stock strategies, with 399 products (222 quantitative long and 141 subjective long), representing approximately 87.5% [1][2]. Group 2: Top Performing Private Equity Firms - A total of 22 billion-yuan private equity firms had all their products reach historical highs in August, with 16 being quantitative and 5 subjective, while 1 was a mixed strategy [2][3]. - The firms with the most products reaching historical highs include JQ Investment (44 products), Junzhijian Investment, and others, with 10 firms having over 10 products achieving this milestone [3][7]. Group 3: Performance Rankings - The average returns of the top 5 private equity firms over the past year are led by Stable Investment, Chengqi Asset, Tianyan Capital, Ningbo Huafang Quantitative, and Minghuo Investment, all of which are quantitative stock strategy firms [4][6]. - The top 5 products in terms of one-year returns are from firms such as Borun Yintai Investment and Heiyi Asset, with a significant number of quantitative long products dominating the rankings [8][11]. Group 4: Long-Term Performance - Over the past three years, the top products are from Abama Investment, Hehehuiyi Asset, and Borun Yintai Investment, with a similar trend of quantitative products leading the rankings [11][17]. - The five-year performance champions include Fusheng Asset and Rido Investment, with both firms having multiple products in the top rankings [17][21].

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 8月，A股市场整体单边震荡上行，沪指站上3800点创下近10年新高，单日成交额最高突破3万亿，市场交投持续火爆，部分基金（公募、私募） 净值也随之创出历史新高。 然而，回顾上一轮结构性牛市，沪指由2019年初低点上涨至2021年2月3731.69的高点，却在随后近1年里于高点附近盘整，并自2022年初起震荡 下跌，迎来了将近3年的熊市行情。 其中， 有不少权益类公募基金和股票多头私募基金正是在 2021年高位时成立的，如今沪指早已"越过"2021年高位的3700多点，那些2021年成 立的基金产品至今收益如何？ 私募排排网数据显示， 截至 2025年8月29日，2021年成立的股票多头私募基金共433只，成立至今实现正收益的 404只，占比93.3% ；根据公募排排网数据，截至2025年8月27日， 2021年成立的权益类公募基金且有业绩展示的（剔除ETF）达1644只，成立 以来正收益产品526只，正收益占比仅32%，相较之下私募基金业绩更为强势 。 那么，有哪些股票多头私募基金收益表现更胜一筹呢？为了给予更多有价值的信息，笔者将筛选出 截至 ...